To accelerate the transition from preclinical studies with laboratory animals to clinical studies with humans, specialists at the biotechnological research laboratory ۳D Bioprinting Solutions (۳DBio) developed a method for the scalable production of 3D spheroids in the quantities necessary to accurately determine the specific activity of pharmacological molecules in the body of COVID-19 infected patients, thus accelerating the discovery process for anti-COVID-19 drugs.
